101 results
8-K
EX-99.2
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
will have wide - ranging benefits for patients and society A30% and25% prevalence in PsA of anxiety and depression 2 4 in 5 patients report … drives psoriatic inflammation alongside IL - 17A… Inhibition of both IL - 17A+IL - 17F provides greater benefits in skin vs. inhibition of IL - 17A only
8-K
EX-99.1
jkjq73je1ak0i 3n
14 Nov 23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-1.1
8g0pq4gof5lfoyy1or
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
424B5
099 vzwy9wp
29 Jun 23
Prospectus supplement for primary offering
4:02pm
424B5
16vznqzderk5z9c 51
26 Jun 23
Prospectus supplement for primary offering
4:23pm
424B5
c3jh5u 34eh9k
11 May 23
Prospectus supplement for primary offering
4:20pm
S-3
EX-4.1
u8viuah
1 May 23
Shelf registration
4:14pm